Published Manuscripts (2008)
Gaede P, , Palmer AJ, Tucker DM, Lammert M, Parving HH, Pedersen O. Cost-effectiveness of intensified versus conventional multifactorial intervention in type 2 diabetes: Results and projections from the Steno-2 study. Diabetes Care 2008; 31(8): 1510-5
Palmer JL, Gibbs M, Scheijbeler HW, Kotchie RW, Nielsen S, White J, . Cost-effectiveness of switching to biphasic insulin aspart in poorly-controlled type 2 diabetes patients in China. Advances in Therapy 2008; 25(8): 752-74
, Tucker D, Palmer AJ, Minshall ME, Foos V, Silberman C. Long-Term Cost-Effectiveness of Pioglitazone versus Placebo in Addition to Existing Diabetes Treatment: A US Analysis Based on PROactive. Value in Health 2008; 12(1): 1-9
, Goodall G, Aagren M, Nielsen S, Palmer AJ, Erny-Albrecht K. Evaluating the cost-effectiveness of therapy conversion to insulin detemir in patients with type 2 diabetes in Germany: a modelling study of long-term clinical and cost outcomes. Advances in Therapy 2008; 25(6): 567-84
Palmer JL, Goodall G, Nielsen S, Kotchie RW, , Palmer AJ, Roze S. Cost-effectiveness of insulin aspart versus human soluble insulin in type 2 diabetes in four European countries: subgroup analyses from the PREDICTIVE study. Current Medical Research and Opinion 2008; 24(5): 1417-28
Ray JA, Borker R, Barber B, , Belozeroff V, Palmer AJ. Cost-Effectiveness of Early versus Late Cinacalcet Treatment in Addition to Standard Care for Secondary Renal Hyperparathyroidism in the USA. Value in Health 2008; 11(5): 800-8
Chirakup S, Chaiyakunapruk N, Chaikledkeaw U, Pongcharoensuk P, Ongphiphadhanakul B, Roze S, , Palmer AJ. Cost-effectiveness analysis of thiazolidinediones in uncontrolled type 2 diabetic patients receiving sulfonylureas and metformin in Thailand. Value in Health 2008; 11(S1): S43-51
Goodall G, Jendle JH, , Munro V, Brandt AB, Ray JA, Roze S, Foos V, Palmer AJ. Biphasic insulin aspart 70/30 vs. insulin glargine in insulin naive type 2 diabetes patients: modelling the long-term health economic implications in a Swedish setting. International Journal of Clinical Practice 2008; 62(6): 869-76
Minshall ME, Oglesby AK, Wintle ME, , Roze S, Palmer AJ. Estimating the long-term cost-effectiveness of exenatide in the United States: an adjunctive treatment for type 2 diabetes mellitus. Value in Health 2008; 11(1): 22-33
Palmer AJ, , Chen R, Mehin N, Gabriel S, Bregman B, Rodby RA. A health economic analysis of screening and optimal treatment of nephropathy in patients with type 2 diabetes and hypertension in the USA. Nephrology Dialysis Transplantation 2008; 23(4): 1216-23
Ali M, White J, Lee CH, Palmer JL, , Fakhoury W, . Therapy conversion to biphasic insulin aspart 30 improves long-term outcomes and reduces the costs of type 2 diabetes in Saudi Arabia. J Med Econ 2008; 11(4): 651-670.
Dial with SkypeOut